Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3226 AL 3240

Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?

Mullane K, Williams M.

Biochem Pharmacol. 2020 Jul;177:113945. doi: 10.1016/j.bcp.2020.113945. Epub 2020 Apr 2.

Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies

Zetterberg H, Bendlin BB.

Mol Psychiatry. 2021 Jan;26(1):296-308. doi: 10.1038/s41380-020-0721-9. Epub 2020 Apr 6.

New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease

Park SA, Han SM, Kim CE.

Exp Mol Med. 2020 Apr;52(4):556-568. doi: 10.1038/s12276-020-0418-9. Epub 2020 Apr 13.

Proteomics as a reliable approach for discovery of blood-based Alzheimer's disease biomarkers: A systematic review and meta-analysis

Rehiman SH, Lim SM, Neoh CF, Majeed ABA, Chin AV, Tan MP, Kamaruzzaman SB, Ramasamy K.

Ageing Res Rev. 2020 Jul;60:101066. doi: 10.1016/j.arr.2020.101066. Epub 2020 Apr 12.

Early Diagnosis and Targeted Treatment Strategy for Improved Therapeutic Outcomes in Alzheimer's Disease

Guest FL, Rahmoune H, Guest PC.

Adv Exp Med Biol. 2020;1260:175-191. doi: 10.1007/978-3-030-42667-5_8.

The Interplay between Diabetes and Alzheimer's Disease-In the Hunt for Biomarkers

Kubis-Kubiak A, Dyba A, Piwowar A.

Int J Mol Sci. 2020 Apr 15;21(8):2744. doi: 10.3390/ijms21082744.

Fluorinated Molecules and Nanotechnology: Future 'Avengers' against the Alzheimer's Disease?

Dabur M, Loureiro JA, Pereira MC.

Int J Mol Sci. 2020 Apr 23;21(8):2989. doi: 10.3390/ijms21082989.

Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease

Mejido DCP, Peny JA, Vieira MNN, Ferreira ST, De Felice FG.

Neuropharmacology. 2020 Jul;171:108115. doi: 10.1016/j.neuropharm.2020.108115. Epub 2020 Apr 25.

Current and Future of Alzheimer's Therapy with the Best Approach

Singh H, Chawla V, Bala R, Dureja H.

CNS Neurol Disord Drug Targets. 2020;19(9):691-697. doi: 10.2174/1871527319666200430000538.

Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals

Qin T, Prins S, Groeneveld GJ, Van Westen G, de Vries HE, Wong YC, Bischoff LJM, de Lange ECM.

Int J Mol Sci. 2020 Apr 30;21(9):3158. doi: 10.3390/ijms21093158.

Combination Drug Therapy for the Management of Alzheimer's Disease

Kabir MT, Uddin MS, Mamun AA, Jeandet P, Aleya L, Mansouri RA, Ashraf GM, Mathew B, Bin-Jumah MN, Abdel-Daim MM.

Int J Mol Sci. 2020 May 5;21(9):3272. doi: 10.3390/ijms21093272.

Clinical significance of fluid biomarkers in Alzheimer's Disease

Lewczuk P, Łukaszewicz-Zając M, Mroczko P, Kornhuber J.

Pharmacol Rep. 2020 Jun;72(3):528-542. doi: 10.1007/s43440-020-00107-0. Epub 2020 May 8.

Editorial: A Is for Amyloid

Selkoe DJ.

J Prev Alzheimers Dis. 2020;7(3):140-141. doi: 10.14283/jpad.2020.27.

Editorial: An Industry Perspective: Future of Anti-Amyloid Trials

Kramer LD.

J Prev Alzheimers Dis. 2020;7(3):142-143. doi: 10.14283/jpad.2020.26.

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease

Khan S, Barve KH, Kumar MS.

Curr Neuropharmacol. 2020;18(11):1106-1125. doi: 10.2174/1570159X18666200528142429.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias